Teresita Briones Ramilo
Child & Adolescent Psychiatry · Indianapolis, INNPI 1144216060
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 464 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$912
- Otsuka America Pharmaceutical, Inc.$595
- Sunovion Pharmaceuticals Inc.$564
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
- AbbVie$464
- Vanda Pharmaceuticals Inc.$437
- plus $3K from 23 others
What the payments were for
- Food & beverage$6,41598%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 87 | $912 |
| Otsuka America Pharmaceutical, Inc. | 46 | $595 |
| Sunovion Pharmaceuticals Inc. | 32 | $564 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $529 |
| AbbVie(2 entities) | 43 | $464 |
| Vanda Pharmaceuticals Inc. | 26 | $437 |
| Neurocrine Biosciences, Inc. | 21 | $336 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $312 |
| Corium, LLC | 23 | $300 |
| Teva Pharmaceuticals USA, Inc. | 17 | $291 |
| Johnson & Johnson | 14 | $257 |
| Lundbeck LLC | 14 | $185 |
| Tris Pharma Inc | 12 | $178 |
| Ironshore Pharmaceuticals Inc. | 10 | $160 |
| Alkermes, Inc. | 6 | $116 |
| Shire North American Group Inc | 6 | $110 |
| Neos Therapeutics, LP | 7 | $109 |
| Axsome Therapeutics, Inc. | 6 | $106 |
| Idorsia Pharmaceuticals US Inc | 1 | $97 |
| Bausch Health US, LLC | 5 | $85 |
| Noven Therapeutics, LLC | 4 | $73 |
| Almatica Pharma LLC | 3 | $58 |
| Indivior Inc. | 4 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $45 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Pernix Therapeutics Holdings, Inc. | 1 | $19 |
How this compares
$6,541 in reported general payments places this provider in the 90th percentile of 56 child & adolescent psychiatry providers in Indiana.
See all child & adolescent psychiatry providers in Indiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 31 | $45,618 |
| RexultiBrexpiprazole | 13 | $18,736 |
| TrintellixVortioxetine Hydrobromide | 23 | $15,255 |
| Lurasidone Hcl | 23 | $14,702 |
| ProzacFluoxetine Hcl | 12 | $8,964 |
| TrileptalOxcarbazepine | 11 | $6,727 |
| Vilazodone Hcl | 25 | $1,858 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $1,326 |
| Ziprasidone Hcl | 15 | $1,150 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $870 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $766 |
| Thioridazine Hcl | 13 | $694 |
| Clonazepam | 66 | $641 |
| Alprazolam | 91 | $618 |
| Hydroxyzine Pamoate | 21 | $575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $464 | $45,61831 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $595 | $18,73613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $312 | $15,25523 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $23420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 child & adolescent psychiatry providers in Indiana.
Other child & adolescent psychiatry in Indianapolis
- Christopher McDougleIndianapolis$17K
- Ann KledzikIndianapolis$12K
- Hugh StarksIndianapolis$4K
- Michael WellingIndianapolis$3K
- David PoseyIndianapolis$3K
- Charles CoatsIndianapolis$2K
- Lucille GotancoIndianapolis$972
- Elizabeth NoceraIndianapolis$841
- Melisa MartinezIndianapolis$769
- Fadia AldahanIndianapolis$571
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.